Put Your Genomics Data to Work — No Bioinformatics Skills Needed
Are complex data analyses delaying YOUR valuable and critical results from being put to action?
Watch this on-demand webinar to learn how the Rosalind™ platform empowers you to analyze your own data, more quickly and cost-effectively — even for the most complex studies.
The fastest path to interactive genomic analysis, RNA-seq gene expression, single-cell expression, CRISPR and many other complex analyses
How the Rosalind™ platform and the OnRamp Bio scientific team can help biologists and other researchers can look deeper into their own data without any bioinformatics skills
About Our Speakers
Jean Lozach joined OnRamp Bio after more than 25 years experience in Genomics, Bioinformatics and Information Technology at Illumina and UCSD. As Associate Director of Enterprise Informatics over the last 5 years, Jean set up and drove customer success for Illumina’s BaseSpace solution for bioinformatics. He uniquely brings deep experience and knowledge of biology, wet lab operations, microarrays, and NGS together with advanced bioinformatics, software development and enterprise IT infrastructure. Jean is an industry expert in genomics and bioinformatics and has led dozens of successful core facility deployments of NGS and informatics systems.
Karl Yoder is a member of the product development and business development teams at OnRamp Bioinformatics. He joins the company after more recently helping to grow a successful biotech focused on therapies involving the human gut microbiome. He earned his MA from UC San Diego and BA from Princeton.
Have genomics data you need to interpret?
Request a free quote from the OnRamp Bioinformatics team!
PALO ALTO, CA, December 11, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced the partnership with Bioinformatics Solutions, Inc. to offer online access to its protein de novo sequencing services to scientists around the globe.
As the creators of the well-known, highly established PEAKS Software, the golden standard of de novo sequencing, Bioinformatics Solutions, Inc., offers their de novo sequencing expertise to scientists at a new level by sequencing the samples themselves.
“Bioinformatics Solutions, Inc. has developed a proprietary de novo protein sequencing workflow to retrieve the amino acid sequence of an unknown antibody protein with state-of-the-art mass spectrometry techniques. Through this workflow, the sequence assembly is purely based on de novo sequencing. Therefore, no database, cDNA, mRNA, or hybridoma cell line is required,” exclaims Baozhen Shan, CEO of Bioinformatics Solutions, Inc. “With constant ongoing research at Bioinformatics Solutions, Inc., the advanced technology will ensure our service delivers a highly accurate sequence, identification of sequence variants, glycosylations, and unknown modifications. By partnering with Science Exchange, these sequencing services will now be available to researchers all over the world to help them make breakthrough discoveries.”
Over the last few years, Science Exchange has undergone extensive growth and recently received a $28 million in Series C funding led by Norwest Venture Partners. By continuing to team up with companies like Bioinformatics Solutions, Inc. Science Exchange is providing researchers worldwide with access to the most important scientific services to advance their experiments.
“We are excited to partner with Bioinformatics Solutions, Inc. to make available its protein de novo sequencing services to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have the services they need securely and readily available to aid their discoveries. Bioinformatics Solutions, Inc. met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of proteomics analysis.”
About Bioinformatics Solutions, Inc.
For more than 15 years, Bioinformatics Solutions, Inc. has been changing the field of proteomics analysis, by pushing the boundaries of its computational limits and striving to provide groundbreaking research with the customer-first approach. Bioinformatics Solutions, Inc. believes the only solution is one that incorporates quality and timely results, a satisfying product experience, customer support and two-way communication. This diverse and adaptable group is committed to serving the needs of pharmaceutical, biotechnological, and academic scientists; and to the progression of recombinant protein production and drug discovery research. For more information, visit www.scienceexchange.com/labs/bioinformatics-solutions-inc. Follow the company on Twitter @PEAKSProteomics and @PEAKSAB.
This is a guest post by Stephen Byers, Director of the Lombardi Shared Resources at the Lombardi Comprehensive Cancer Center, Georgetown University (full bio below).
Different core facilities develop specializations, driven both by foresight as well as serendipity. Georgetown, for example, has invested in an outstanding Metabolomics Shared Resource Program. We’re finding that, in many cases, high throughput analysis of metabolites in blood or urine with LC-Mass Spectrometry is as good as genomic profiling at segregating outcomes in diseases… and a whole lot cheaper. We can generate as many as 20-30,000 metabolite data points in an hour at $60/hr for 6 samples. The real challenge for this field, as for much of post-genomic science, is the informatics that goes into analyzing all this data. Under the guidance of our metabolomics gurus, Al Fornace and Amrita Cheema, and Medical Informatics Director Subha Madhavan, we are improving our informatics services and finding no shortage of investigators eager to take advantage of this technology.
Karl Yoder is a member of the product development and business development teams at OnRamp Bioinformatics. He joins the company after more recently helping to grow a successful biotech focused on therapies involving the human gut microbiome. He earned his MA from UC San Diego and BA from Princeton.
Follow Us